Bibliographic information
GuidelineWHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update
Year of Publication2022
Issuing InstitutionWorld Health Organization
Recommendation
New
Starting antiretroviral therapy in patients on multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) regimens: Antiretroviral therapy is recommended for all patients with HIV and drug-resistant tuberculosis requiring second-line antituberculosis drugs, irrespective of CD4 cell count, as early as possible (within the first 8 weeks) following initiation of antituberculosis treatment.
Recommended in favor
Strong
Certainty of evidence
Very low